
Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium - Based Contrast Agents
Friday, May 14, 2010 - Saturday, May 15, 2010
Presented By
Presented by Yale School of Medicine and the New York Academy of Sciences
In 1997, a new disease was recognized among patients with pre-existing renal dysfunction. Now known as Nephrogenic Systemic Fibrosis (NSF), the disorder is known to be highly associated with, and very likely triggered by, gadolinium based magnetic resonance imaging contrast agents (GBCA). As such, it is a man-made disease, very likely a hitherto uncharacterized fibrosing toxicity to heavy metal deposition in the human body. Much of what we know about NSF stems from the NSF Registry at Yale University, and, in recent years, an annual scientific meeting on NSF hosted at Yale.
The May 2010 Fourth Annual Meeting on NSF and GBCA will have several goals. As the 4th meeting represents a change in venue from New Haven, CT to New York City, a very important aspect will be introducing the disease to a new, and much larger community of practitioners and scientists, chiefly in nephrology, radiology, rheumatology, dermatology and pathology. The introductory sessions will provide the historical context of NSF—how it was discovered, the mechanics of how it is diagnosed, and the significance of gadolinium micro-detection. The core of the meeting will focus on the mechanism of fibrosis in NSF—these derived from animal and tissue culture studies. The discussion will be broadened to include known mechanisms of tissue fibrosis (systemic and organ specific) and potential targets of pharmacologic therapy. Lastly, we will examine the lessons learned from NSF: the current state of prevention, and practical strategies for using GBCA wisely in those at risk.
Overall, the breadth of discussions will extend from the cells and atoms responsible for NSF to the entire population at risk, and therapeutically and mechanistically from the scientific bench-top to the bedside. Of greater importance, perhaps, is the impact this work will have on the fundamental understanding of fibrosis in general, opening up new avenues of understanding into disease mechanisms previously thought to be unchallengeable by medicine.
For more information about this symposium, please go to the Yale CME website.
Symposium Co-Chairs
Ali K. Abu-Alfa, MD
Yale School of Medicine
Shawn Cowper, MD
Yale School of Medicine
The International Center for Nephrogenic Systemic Fibrosis Research
Scientific Program Director
Richard Bucala, MD, PhD
Yale School of Medicine
Clinical Program Director
Jeffrey Weinreb, MD
Yale School of Medicine
Consulting Faculty and Program Content Reviewer
Marcus W. Bosenberg
Yale School of Medicine
Learning Objectives
Participants who attend this conference will be able to:
- • Receive updated information on the diagnosis and treatment of NSF.
- • Review current understanding of the pathophysiology of NSF .
- • Recognize important differences among the various GBCA.
- • Discuss the impact on patient care and practice management.
- • Discuss strategies to identify patients with kidney disease who might be at risk.
Accreditation Statement
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.
Designation Statement
The Yale School of Medicine designates this educational activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure Policy
It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.
Presented by
Related Event
Inaugural Global Fibrosis Foundation Fundraising Dinner
May 14, 2010 | 8:00PM
Separate from the scientific symposium, the Global Fibrosis Foundation will hold their inaugural fundraising event. For information and to reserve tickets please visit http://www.globalfibrosis.org/funds.html or contact Carol Hribko at hribko.globalfibrosis@gmail.com.
*Image kindly donated by Shawn Cowper: Heart muscle (red) entwined in fibrous collagen (blue) from a young NSF patient (Trichrome stain)
Agenda
*Presentation times are subject to change.
Friday, May 14, 2010 | |
12:00 PM | Registration |
12:30 PM | Welcome |
Session IModerator: Henrik S. Thomsen, MD, University of Copenhagen and Copenhagen University Hospital | |
12:40 PM | Nephrogenic Systemic Fibrosis: Definition, Systemic Effects and Disease Course |
1:10 PM | Nephrogenic Systemic Fibrosis and GBCA: Radiology Revelations |
1:40 PM | Update on imatinib Treatment in NSF |
2:10 PM | Refreshment Break & Poster Reviews |
2:30 PM | Detection of Gadolinium in Tissues: What does it Mean, Exactly? |
3:00 PM | NSF and GBCA: Pharmacovigilance and Regulatory Actions in the US |
3:30 PM | Q&A |
4:00 PM | Platform Presentations |
Keynote Lecture | |
5:00 PM | The Discovery of NSF |
5:45 PM | Reception |
Saturday, May 15, 2010 | |
7:30 AM | Registration and Continental Breakfast |
Session IIModerator: Richard Bucala, MD, PhD, Yale School of Medicine | |
8:30 AM | The Pathophysiology of Fibrosis |
9:20 AM | The Role of Osteopontin in Fibrosis |
9:40 AM | GBCA and the Induction of Matrix Production |
10:00 AM | Refreshment Break & Poster Viewing |
10:30 AM | Impact of GBCA on Fibrocyte Function |
11:00 AM | Fibrosis Roundtable |
Session III: Part 1Gadolinium: Its Theoretical and Observed Effects in vivo - Models and Their Validity: | |
11:30 AM | Sheffield Experience |
11:45 AM | University of California San Francisco Experience |
12:00 PM | Lunch |
Session III: Part 2 | |
1:00 PM | GBCA Structures and Physiochemical Properties (Guerbet) |
1:15 PM | The Bayer Schering Pharma AG Experience |
1:30 PM | The GE Healthcare Experience |
1:45 PM | The Array Biopharma Experience |
2:00 PM | Panel Discussion |
2:30 PM | Refreshment Break & Poster Defense |
SESSION IVModerator: Jeffrey Weinreb, MD, Yale School of Medicine | |
3:15 PM | Approach to the Use of GBCA in Patients with Kidney Disease |
3:45 PM | Panel Discussion - Controversies in the Continued Use of GBCAs Panel: |
5:15 PM | Closing Statements |
5:30 PM | Adjourn |
Speakers
Symposium Co-Chairs
Ali K. Abu-Alfa, MD
Yale School of Medicine
Shawn Cowper, MD
Yale School of Medicine
The International Center for Nephrogenic Systemic Fibrosis Research
Speakers
Richard Bucala MD, PhD
Yale School of Medicine
April Cox, MS
Array Biopharma
Michael Edward, PhD
University of Glasgow, Glasgow, UK
Jack Gauldie, PhD
McMaster University
Michael Girardi, MD
Yale School of Medicine
John Haylor, PhD
University of Sheffield
Whitney A. High, MD, MEng
University of Colorado, Denver
Thomas Hope, MD
Univeristy of California, San Francisco
Jean-Marc Idée, PharmD, MS
Guerbet
Emanuel Kanal, MD, FACR, FISMRM, AANG
University of Pittsburgh Medical Center
Jonathan Kay, MD
University of Massachusetts Medical School
Ira Krefting, MD
Food and Drug Administration
Phillip H. Kuo MD, PhD
University of Arizona School of Medicine
Philip E. LeBoit, MD
University of California San Francisco
Sameh K. Morcos FRCS, FFRRCSI, FRCR
Sheffield Teaching Hospitals
Benjamin Newton, PhD
GE Healthcare
Susanne Nicholas, MD, PhD
University of California, Los Angeles
Hubertus Pietsch, DVM
Bayer Schering Pharma AG
Martin R. Prince, MD PhD
Cornell & Columbia Universities
Martin A. Sieber, PhD
Bayer Schering Pharma AG
Sundararaman Swaminathan, MD
University of Arkansas for Medical Sciences
Henrik S. Thomsen, MD
University of Copenhagen and Copenhagen University Hospital
Jeffrey C. Weinreb, MD
Yale School of Medicine
Supporters
For opportunities to support or exhibit at this event, please contact Deborah Dunn at deborah.dunn@yale.edu or 203.785.4578.
Presented by
Bronze
Academy Friends
- • This event is funded in part by the Life Technologies™ Foundation.
- • This symposium is endorsed by New York Society of Nephrology.
- • Amgen
- • Bayer
- • Department of Dermatology, Yale School of Medicine
- • General Electric
- • Guerbet
- • Lantheus
- • The Global Fibrosis Foundation
Grant Support
The project described is supported by Award Number R13DK088440 from the National Institute Of Diabetes And Digestive And Kidney Diseases. The content of this program is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of Diabetes And Digestive And Kidney Diseases or the National Institutes of Health.
Promotional Partner
Travel & Lodging
Our Location
The New York Academy of Sciences
7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157
212.298.8600
Hotels Near 7 World Trade Center
Recommended partner hotel:
Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
Phone: (212) 577-1133
Located on the south side of the World Trade Center, opposite Memorial Plaza, Club Quarters, 140 Washington Street, is just a short walk to our location. The New York Academy of Sciences is a part of the Club Quarters network. Please feel free to make accommodations on-line to save significantly on hotel costs.
Password: NYAS
Other hotels located near 7 WTC:
212.945.0100 |
212.693.2001 |
212.385.4900 |
212.693.2001 |
212.269.6400 |
212.742.0003 |
212.232.7700 |
212.747.1500 |
212.344.0800 |